| |
Aggregate Spend Solutions and Regulatory Compliance Products
Porzio Life Sciences’ regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations, including PDMA, anti-kickback statutes, False Claims Act, FDA, OIG, Physician Payments Sunshine Act, Affordable Care Act and state aggregate spend compliance regulations.
Porzio AggregateSpendID® is an automated web-based solution for spend and samples data capture, tracking and reporting. The system collects spend associated with sales representatives, senior executives, medical meetings, clinical trials, grants, eGrants, speaking fees, honoraria, etc.
Products and Services
Porzio AggregateSpendID®— Web-based system to track spend and samples directed towards healthcare providers and organizations - read more ►
|
News
Porzio celebrates its 3rd Annual National Customer Service Week! - read more
AdvaMed is the world’s largest medical technology association representing manufacturers of medical devices, diagnostics products, and medical information systems - read more
Christine Bradshaw and Sarah Canberg Quoted in Article on the Sunshine Act’s Complexity►
Christine N. Bradshaw, Associate of Porzio, Bromberg & Newman and Director of Regulatory and Compliance Services of Porzio Life Sciences, LLC and Sarah M. Canberg, Associate of Porzio, Bromberg & Newman and Manager of Regulatory and Compliance Services of Porzio Life Sciences, LLC are quoted in the Compliance Week article "Final Version Provides Little Relief for Complex Sunshine Act.” - read more or go to Compliance Week►
Scott Liebman and Christine Bradshaw Quoted in Article on the Finalization of the Sunshine Act ►
Scott Liebman, Principal of Porzio, Bromberg & Newman and Vice President of Porzio Life Sciences and Christine Bradshaw, Associate of Porzio, Bromberg & Newman and Director of Regulatory and Compliance Services of Porzio Life Sciences are quoted in the article "The Sunshine Act is Finally Final" in the Pharma & Healthcare section of Forbes.com - read more or go to Forbes
Elizabeth Kim & Kiaema Reid, Co-Authors of Compliance Manual ►
Porzio Life Sciences’s Elizabeth H. Kim, Manager of Regulatory and Compliance Services and Kiaema Reid, Senior Regulatory Analyst, are contributors to the composition of the “Pharmaceutical and Medical Device Compliance Manual,” - read more
More News►
Careers
read more ►
|
Events
American Conference Institute’s 14th National Pharmaceutical Compliance & Enforcement Forum ►
Christine Bradshaw is speaking and a panelist on the Sunshine Act Compliance Boot Camp: Preparing, Modifying, and Monitoring Data Collection and Reporting Systems. Takes place on March 19-20, 2014 - Read more
The Pharmaceutical Compliance Forum Spring 2014 Meeting ►
Timothy Ayers speaking at the Pharmaceutical Compliance Forum Spring 2014 Members-Only Meeting on March 11, 2014 - Read more
2014 Disorders of the Spine and Peripheral Nerves Annual Meeting ►
Ed Crowe will be speaking at the 2014 Disorders of the Spine and Peripheral Nerves Annual Meeting on March 6, 2014 - Read more
Synergistix 10th Annual Users Conference ►
John Patrick Oroho spoke at the Synergistix 10th Annual Users Conference on March 5-7, 2014 - Read more
Practical Law Company 2nd Annual Life Sciences Law Forum ►
D. Jeffrey Campbell spoke and Christine Bradshaw attended PLC Life Sciences 2nd Annual Life Sciences Law Forum on March 5, 2014 - Read more
DIA Marketing Pharmaceuticals 2014: Regulating Drug Marketing in the Ever-Changing Regulatory / Legal / Healthcare Environment Workshop ►
Christine Bradshaw spoke on Marketing Prescription Products in the Age of Obama on February 27-28, 2014 - Read more
CBI Oncology Commercialization & Market Access Conference ►
Timothy Ayers spoke at the CBI Oncology Commercialization & Market Access Conference in Philadelphia, PA on February 25, 2014 - Read more
Michelle Axelrod and Timothy Ayers Co-Presented The FDA Is Watching Webinar ►
The February 11, 2014 webinar revealed the FDA’s monitoring practices of promotional activities which now include websites, Twitter, journal articles, TV appearances, Facebook; as well as medical meetings and industry trade shows - Read more
Sixth Annual Summit On Disclosure, Transparency And Aggregate Spend For Drug, Device And Biotech Companies ►
Domestically pharma and device companies are in the heart of their efforts to meet the March 2014 reporting date mandated by the Physician Payments Sunshine Act on February 5-7, 2014 - read more
2nd Annual Global Pharmaceutical and Medical Meetings Summit ►
John spoke on the Highlights of Pharmaceutical and Health Care Regulations and the Trends and Impact on Your Meetings on February 3-5, 2014 - read more
More Events►
Articles
FDA’s Office of Prescription Drug Promotion (OPDP) Enforcement: A Summary of 2013 Warning and Untitled Letters ►
FDA’s Office of Prescription Drug Promotion (OPDP) issued a total of 24 enforcement letters to pharmaceutical manufacturers in 2013, 3 Warning Letters and 21 Untitled Letters - read more
Getting the Deal Through: Life Sciences 2014 - United States Chapter Life Sciences in 24 Jurisdictions Worldwide ►
Article by John Patrick Oroho and Brian P. Sharkey - “In recent years, the United States has seen a significant increase in federal and state government-initiated enforcement actions against life sciences companies, many of which have resulted in multi-million, or even multi-billion, dollar settlements and penalties - read more
Bloomberg BNA Pharmaceutical Law & Industry Report
Porzio Life Sciences, LLC
EFPIA Leads the Self-Regulation Charge to Try to Avoid Government-Imposed Transparency ►
The debate between government-imposed disclosure requirements and industry self-regulation supporters continues to heat up around the world. In this update, D. Jeffrey Campbell and Brian P. Sharkey discuss how the European Federation of Pharmaceutical Industries and Associations (EFPIA) is leading the movement toward self-regulation by its recent adoption of a new disclosure code - read more
|
|